H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Immunovant to $17 from $16 and keeps a Buy rating on the shares. The company had a "fairly uneventful earnings release after a period of significant activity," Tsao tells investors in a research note.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on IMVT:
- Immunovant to Present at Guggenheim 4th Annual Immunology and Neurology Day on November 14th
- Immunovant announces anticipated milestones
- Immunovant reports Q2 EPS (41c), consensus (39c)
- Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended September 30, 2022
- Immunovant management to meet with Truist
